| Q33188355 | 14-3-3 proteins in the nervous system |
| Q35753388 | A review of the treatment options for Huntington's disease |
| Q36719669 | A systematic review of the treatment studies in Huntington's disease since 1990. |
| Q38624994 | Advancing pharmacotherapy for treating Huntington's disease: a review of the existing literature |
| Q28476789 | An International Survey-based Algorithm for the Pharmacologic Treatment of Irritability in Huntington's Disease |
| Q30660685 | An overview of psychiatric symptoms in Huntington's disease |
| Q38830416 | Antipsychotic drugs in Huntington's disease. |
| Q33734410 | Cell Therapy Strategies vs. Paracrine Effect in Huntington's Disease |
| Q34346879 | Chorea and related disorders. |
| Q38244078 | Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches? |
| Q33734563 | Dissecting the Molecular Mechanisms of Neurodegenerative Diseases through Network Biology |
| Q30477000 | Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series. |
| Q37488273 | Emerging drug therapies in Huntington's disease |
| Q37962584 | Epigenetic treatment of neurological disease |
| Q82993834 | Huntington's Disease |
| Q92106147 | International Guidelines for the Treatment of Huntington's Disease |
| Q38215303 | Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors |
| Q38927030 | Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect |
| Q44263695 | Olanzapine-associated seizure |
| Q34284039 | Preclinical and clinical investigations of mood stabilizers for Huntington's disease: what have we learned? |
| Q73965156 | Psychosis Due to Neurologic Conditions |
| Q44208372 | Quetiapine in Huntington's disease: a first case report |
| Q43907868 | Riluzole and olanzapine in Huntington's disease |
| Q37131233 | Symptomatic treatment of Huntington disease |
| Q36070777 | Systems Genetic Analyses Highlight a TGFβ-FOXO3 Dependent Striatal Astrocyte Network Conserved across Species and Associated with Stress, Sleep, and Huntington's Disease |
| Q38019159 | Targeting Huntington's disease through histone deacetylases |
| Q37774037 | Targeting histone deacetylases for the treatment of Huntington's disease. |
| Q39041214 | Targeting the Cholinergic System to Develop a Novel Therapy for Huntington's Disease |
| Q24626017 | Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder |
| Q53716390 | Therapy development in Huntington disease: From current strategies to emerging opportunities. |
| Q34054609 | Treatment of Irritability in Huntington’s Disease |
| Q42052656 | Treatment of huntington disease |
| Q37249765 | Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders |
| Q44761187 | Ziprasidone in Huntington's disease: the first case reports |